Skip to main
KYTX
KYTX logo

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc is experiencing an optimistic outlook due to heightened confidence in its lead product, KYV-101, which shows promising durability and effectiveness in treating myasthenia gravis (MG) and other autoimmune diseases. The probability of approval for KYV-101 in MG has been raised significantly, reflecting the strong initial responses observed in compassionate-use patients and a favorable safety profile. Additionally, the company has received favorable comparisons to existing therapies, with KYV-101 outperforming rituximab in randomized cohorts, reinforcing its potential as a leading candidate in the CAR-T therapy space for immunology and inflammation (I&I).

Bears say

Kyverna Therapeutics Inc faces significant challenges regarding the durability of responses for its product candidate, KYV-101, in lupus nephritis (LN) and myasthenia gravis (MG), raising concerns about the long-term efficacy of the treatment as the dataset matures. The company may also encounter difficulties in generating positive clinical data for its second product, KYV-101, in seropositive systemic disease (SPS), which could adversely impact its therapeutic portfolio. Additionally, potential long-term dilution risks pose a financial threat, further contributing to a negative outlook for the company’s stock.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.